David Vallerand, Director of Scientific Engagement for Crown Bioscience, examines the technologies advancing cell and gene therapy drug discovery.   Transforming CGT development through next-generation preclinical models   Introduction Cell and gene therapy (CGT) is transforming the field of oncology. Unlike traditional cytotoxic treatments, CGT leverages the body’s immune system and targets the genetic drivers of cancer to provide more precise and effective […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!